Semaglutide

2mg Vial

5mg Vial

10mg Vial

15mg Vial

20mg Vial

30mg Vial

29 August 2026Updated 29 August 2026

Semaglutide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Semaglutide.

Create free account Member login

Full range of benefits for Semaglutide

Lowers HbA1c and improves overall glycaemic control

Stimulates glucose-dependent insulin secretion

Suppresses inappropriate glucagon release to lower hyperglycaemia

Delays gastric emptying, reducing postprandial glucose spikes

Reduces appetite and caloric intake, supporting weight loss in trials

Associated with reduced major adverse CV events in high-risk patients

May reduce progression of diabetic kidney disease markers in studies

Lowers systolic blood pressure modestly in clinical studies

Improves some lipid and inflammatory markers (eg, triglycerides)

Available as once-weekly injectable or daily oral formulation for flexibility

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 13 known interactions

Synergistic(2)Compatible(4)Monitor(3)Avoid(4)

Not recommended for concurrent use

DPP-4 inhibitors (e.g., sitagliptin)

DPP-4 inhibitors provide little incremental benefit when combined with a GLP-1 receptor agonist due to overlapping incretin pathway effects and are generally unnecessary.

Pramlintide (amylin analog)

Pramlintide plus semaglutide can produce additive slowing of gastric emptying, nausea and increased hypoglycaemia risk (particularly with insulin), so combined use requires careful specialist assessment.

Levothyroxine (and other orally administered narrow therapeutic index drugs)

Semaglutide delays gastric emptying and may alter absorption of orally administered drugs with narrow therapeutic indices, so timing, monitoring and dose review are recommended when starting or stopping semaglutide.

Opioids and other medications that markedly slow gastric emptying

Co-administration may lead to additive delays in gastric emptying and worsening gastrointestinal adverse effects, warranting careful evaluation of symptomatic risk and necessity.

All interaction categories

Synergistic (2)

Metformin: Metformin and semaglutide provide complementary glucose-lowering mechanisms with additive HbA1c reduction and are a common, effective combination in type 2 diabetes management.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): SGLT2 inhibitors act via insulin-independent urinary glucose excretion and, when combined with semaglutide, often produce additive glycaemic control, greater weight loss and complementary cardio-renal benefits.

Compatible (4)

Statins (e.g., atorvastatin): Statins have no pharmacodynamic or pharmacokinetic interaction with semaglutide and are routinely co-administered for cardiovascular risk management.
ACE inhibitors / ARBs (e.g., ramipril, losartan): ACE inhibitors and ARBs are hemodynamically and metabolically compatible with semaglutide and require no routine dose adjustment when co-administered.
Proton pump inhibitors (e.g., omeprazole): Proton pump inhibitors do not have clinically meaningful interactions with semaglutide and are generally safe to use concurrently.
Combined oral contraceptives: Combined oral contraceptives have no consistent clinically important interaction with semaglutide, though adherence counseling remains important during weight-loss therapy.

Monitor (3)

Insulin (especially prandial/basal insulin): Adding semaglutide to insulin regimens commonly improves glycaemia but increases hypoglycaemia risk unless insulin doses and glucose are closely monitored and adjusted.
Sulfonylureas (e.g., glimepiride, gliclazide): Concomitant use of sulfonylureas with semaglutide raises hypoglycaemia risk, so blood glucose monitoring and consideration of sulfonylurea dose reduction are warranted.
Warfarin (vitamin K antagonists): Semaglutide can alter oral drug absorption and nutritional intake which may affect INR stability, therefore more frequent INR monitoring is advisable after initiation or dosage changes.

Avoid (4)

DPP-4 inhibitors (e.g., sitagliptin): DPP-4 inhibitors provide little incremental benefit when combined with a GLP-1 receptor agonist due to overlapping incretin pathway effects and are generally unnecessary.
Pramlintide (amylin analog): Pramlintide plus semaglutide can produce additive slowing of gastric emptying, nausea and increased hypoglycaemia risk (particularly with insulin), so combined use requires careful specialist assessment.
Levothyroxine (and other orally administered narrow therapeutic index drugs): Semaglutide delays gastric emptying and may alter absorption of orally administered drugs with narrow therapeutic indices, so timing, monitoring and dose review are recommended when starting or stopping semaglutide.
Opioids and other medications that markedly slow gastric emptying: Co-administration may lead to additive delays in gastric emptying and worsening gastrointestinal adverse effects, warranting careful evaluation of symptomatic risk and necessity.